The loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with predominant schizophrenic negative symptoms by Wyss, Christine et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
The loudness dependence of auditory evoked potentials (LDAEP) as an
indicator of serotonergic dysfunction in patients with predominant
schizophrenic negative symptoms
Wyss, Christine; Hitz, Konrad; Hengartner, Michael P; Theodoridou, Anastasia; Obermann, Caitriona;
Uhl, Idun; Roser, Patrik; Grünblatt, Edna; Seifritz, Erich; Juckel, Georg; Kawohl, Wolfram
Abstract: Besides the influence of dopaminergic neurotransmission on negative symptoms in schizophre-
nia, there is evidence that alterations of serotonin (5-HT) system functioning also play a crucial role in
the pathophysiology of these disabling symptoms. From post mortem and genetic studies on patients
with negative symptoms a 5-HT dysfunction is documented. In addition atypical neuroleptics and some
antidepressants improve negative symptoms via serotonergic action. So far no research has been done to
directly clarify the association between the serotonergic functioning and the extent of negative symptoms.
Therefore, we examined the status of brain 5-HT level in negative symptoms in schizophrenia by means
of the loudness dependence of auditory evoked potentials (LDAEP). The LDAEP provides a well estab-
lished and non-invasive in vivo marker of the central 5-HT activity. We investigated 13 patients with
schizophrenia with predominant negative symptoms treated with atypical neuroleptics and 13 healthy
age and gender matched controls with a 32-channel EEG. The LDAEP of the N1/P2 component was
evaluated by dipole source analysis and single electrode estimation at Cz. Psychopathological parameters,
nicotine use and medication were assessed to control for additional influencing factors. Schizophrenic pa-
tients showed significantly higher LDAEP in both hemispheres than controls. Furthermore, the LDAEP
in the right hemisphere in patients was related to higher scores in scales assessing negative symptoms.
A relationship with positive symptoms was not found. These data might suggest a diminished central
serotonergic neurotransmission in patients with predominant negative symptoms.
DOI: 10.1371/journal.pone.0068650
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-81789
Published Version
 
 
Originally published at:
Wyss, Christine; Hitz, Konrad; Hengartner, Michael P; Theodoridou, Anastasia; Obermann, Caitriona;
Uhl, Idun; Roser, Patrik; Grünblatt, Edna; Seifritz, Erich; Juckel, Georg; Kawohl, Wolfram (2013). The
loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunc-
tion in patients with predominant schizophrenic negative symptoms. PLoS ONE, 8(7):e68650. DOI:
10.1371/journal.pone.0068650
The Loudness Dependence of Auditory Evoked
Potentials (LDAEP) as an Indicator of Serotonergic
Dysfunction in Patients with Predominant Schizophrenic
Negative Symptoms
Christine Wyss1, Konrad Hitz1, Michael P. Hengartner1, Anastasia Theodoridou1, Caitriona Obermann1,
Idun Uhl2, Patrik Roser2, Edna Gru¨nblatt3, Erich Seifritz1, Georg Juckel2., Wolfram Kawohl1*.
1Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, Zurich, Switzerland, 2Department of Psychiatry, Ruhr University
Bochum, LWL University Hospital, Bochum, Germany, 3Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland
Abstract
Besides the influence of dopaminergic neurotransmission on negative symptoms in schizophrenia, there is evidence that
alterations of serotonin (5-HT) system functioning also play a crucial role in the pathophysiology of these disabling
symptoms. From post mortem and genetic studies on patients with negative symptoms a 5-HT dysfunction is documented.
In addition atypical neuroleptics and some antidepressants improve negative symptoms via serotonergic action. So far no
research has been done to directly clarify the association between the serotonergic functioning and the extent of negative
symptoms. Therefore, we examined the status of brain 5-HT level in negative symptoms in schizophrenia by means of the
loudness dependence of auditory evoked potentials (LDAEP). The LDAEP provides a well established and non-invasive
in vivo marker of the central 5-HT activity. We investigated 13 patients with schizophrenia with predominant negative
symptoms treated with atypical neuroleptics and 13 healthy age and gender matched controls with a 32-channel EEG. The
LDAEP of the N1/P2 component was evaluated by dipole source analysis and single electrode estimation at Cz.
Psychopathological parameters, nicotine use and medication were assessed to control for additional influencing factors.
Schizophrenic patients showed significantly higher LDAEP in both hemispheres than controls. Furthermore, the LDAEP in
the right hemisphere in patients was related to higher scores in scales assessing negative symptoms. A relationship with
positive symptoms was not found. These data might suggest a diminished central serotonergic neurotransmission in
patients with predominant negative symptoms.
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Introduction
Negative symptoms are core features of schizophrenia and are
generally considered in psychiatric scales [1] and diagnostic
classification, e.g. in the DSM-IV-TR [2]. These symptoms
describe a deficit or an absence of normal mental functions and
have traditionally been considered to consist of affective flattening,
alogia, avolition, anhedonia and attentional impairment [3].
Research in this field has characterised negative symptoms to
occur as accompanying symptoms of positive symptoms (e.g.
hallucinations, delusion and formal thought disturbances) and
both in the prodromal and residual state of the disease. They are
named primary negative symptoms if directly related to the disease
process itself and not resulted in a secondary action from other
psychiatric symptoms or medication side effects [4]. Negative
symptoms often lead to social impairment, resulting in poor
success in social and professional life and account for much of the
long-term morbidity and poor functional outcome of patients with
schizophrenia [5,6]. Despite that, the pathophysiology of negative
symptoms has been widely unknown so far.
Schizophrenia research on biochemical functions has largely
focused on the dopamine neurotransmitter system. The dopamine-
hypothesis based on imaging studies proposes an imbalance of
cortical and subcortical preponderance of dopaminergic neuro-
transmission, where a subcortical hyperstimulation of dopamine
D2-receptors leads to positive symptoms, and a hypoactivation of
cortical dopamine D1-receptors leads to negative and cognitive
symptoms [7,8,9,10]. However, the theory of a serotonin (5-
hydroxytrypamine, 5-HT) and dopamine interaction as the
mechanism behind schizophrenia has gained more acceptance.
Moreover, there is evidence that the serotonin system inhibits
dopamine function in frontal cortex and reinforce the imbalance
in the mesolimbic-mesocortical pathway of the dopaminergic
system [11,12,13,14,15]. The involvement of the serotonergic
system in this theory is due to the fact that atypical neuroleptics
[16,17,18] and antidepressants [19,20,21], which act via the
serotonergic system, show remarkable potency for the treatment of
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negative symptoms. Meltzer [22] specifies that 5-HT2A receptor
antagonism and 5-HT1A partial agonism together with weak
dopamine D2 receptor antagonism are responsible for the
principal pharmacologic effects of atypical neuroleptics on
negative symptoms. An addendum to the former concept was
that this new hypothesis allows explaining the heterogeneity of
schizophrenia even better. Since a single type of abnormality of
the neurotransmitter systems is unlikely to emerge as characteristic
of all patients with schizophrenia. To sum up, there is evidence
that the serotonergic system is a key component in the
pathogenesis of negative symptoms.
The serotonin system plays an important role in pathophysiol-
ogy of the major psychiatric disorders and provides a target of
pharmacotherapeutic interventions. Therefore reliable indicators
of this system are in urgent need for clinical and scientific interest
[23]. Such indicators could be used after overcoming some
challenges concerning the implementation in daily clinical use to
identify patients with serotonergic dysfunctions and thus serve as
therapy predictors [24,25]. In fact, common indicators of the
serotonin system are mainly indirect peripheral parameters that
only give an approximate indication of the central serotonergic
system. Such methods as neuroendocrinological challenge tests,
measuring concentrations of serotonin metabolites in cerebrospi-
nal fluid and tryptophan depletion test have not been proven to be
sufficiently valid [26]. Furthermore, the use of imaging techniques
that allow to reflect the availability of binding potentials of
serotonin transporter (SERT) or 5-HT receptors, such as positron
emission tomography (PET) [27] and single photon emission
computed tomography (SPECT), are not appropriate for daily
clinical use because of their invasive properties [15].
In the continuing search for biological correlates of psychiatric
disorders, evoked potentials now constitute a prime target of
investigation. In particular, the loudness dependence of auditory
evoked potentials (LDAEP) has been widely reported to be a valid
measure of central serotonergic activity in humans
[25,28,29,30,31,32]. This measure represents a growth of the
amplitude in primary auditory cortices, measured from the peak of
the N1 to the peak of the P2 component along with an increase in
sound pressure level (Figure S1). A pronounced LDAEP suppos-
edly reflects a low central serotonergic neurotransmission and vice
versa. Some other reports have suggested that the interpretation
may be more complex and the LDAEP’s specificity as a marker of
serotonin function has been challenged [33,34,35,36].
A significant body of research documents a weaker LDAEP in
patients with schizophrenia compared to healthy controls, thus
indicating increased serotonergic activity in patients [37,38,39,40].
But this research to date has tended to focus on the diagnosis of
schizophrenia, neglecting the clinical heterogeneity. However, it is
of great interest to investigate schizophrenia on the psychopath-
ological symptom level. Thus, the aim of the current study is to
scrutinize the putative role of serotonergic neurotransmission of
negative symptoms in schizophrenia.
Methods
Subjects
The sample included 26 male subjects (13 patients, 13
controls) who underwent electrophysiological recording. Subjects
with psychiatric comorbidity, drug or alcohol abuse, benzodi-
azepine consumption for more than 10 days before examination
or a lifetime history of neurological diseases were excluded.
Thirteen patients with predominant negative symptoms recruit-
ed from the Department of General and Social Psychiatry at
the Psychiatric University Hospital Zurich met the diagnostic
criteria for chronic paranoid schizophrenia in accordance to
ICD-10 [41]. The psychopathological state of all patients was
rated based on the Positive and Negative Syndrome Scale
(PANSS; [42]) and the Scale for Assessment of Negative
Symptoms (SANS; [1]). To differentiate depressive symptoms
from negative symptoms, Hamilton Depression Rating Scale
(HAMD; [43]), Bech-Rafaelsen Melancholia Scale (BRMES;
[44]) and Calgary Depression Rating Scale for Schizophrenia
(CDSS-G; [45]) were applied. All patients were using atypical
antipsychotics during the test period. Dosages were transformed
into chlorpromazine (CPZ) equivalent values for comparative
reasons [46]. Thirteen healthy, age- and gender-matched
volunteers recruited from medical staff and students served as
the control group. Controls with a lifetime history of any
psychiatric disorder were excluded.
Ethics Statement
The study was approved by the special subcommission for
psychiatry of the ethics committee of the canton of Zurich (‘‘SPUK
ZH Psychiatrie’’) under the title ‘‘Die Rolle der zentralen
serotonergen Aktivita¨t bei Negativsymptomen’’ (Ref.-Nr.: E-19/
2006) and was carried out in accordance with the Declaration of
Helsinki. All subjects have given written informed consent. Only
participants with uncompromised capacity to consent were
approached. The capacity to give consent had been established
by the senior consultant psychiatrists responsible for the treatment
of the patients.
Electrophysiological Assessment
Subjects were seated with their eyes open in a quiet room
adjacent to the recording apparatus and were asked to avoid facial
muscle movements throughout the auditory stimulus presentation
sequence and the recording. As attention to the auditory stimuli
has been shown to modulate the auditory evoked potentials [47]
and therefore also the LDAEP [48], a silent movie was shown to
them for distraction and the stimuli were presented in randomized
orders and points in time that precluded preparatory state.
Auditory evoked potential (AEP)-recording was performed with 32
electrodes referenced to FCz (BrainCap-MR 32 standard, 32
channels, Easycap, Herrsching-Breitbrunn) in accordance with the
international 10–20 System [49]. Scalp electrode impedances were
kept below 10 kV. Sinus tones (1 000 Hz, 40 ms duration with
10 ms rise and fall time, ISI randomized between 1 800 and 2
240 ms) of five intensities (60, 70, 80, 90, 100 dB sound pressure
level, generated by a PC-stimulator) were presented binaurally in a
pseudo-randomized order over headphones using PRESENTATION
software (Neurobehavioral Systems, Inc. San Pablo, CA). Data
were collected with a sampling rate of 250 Hz and a band pass
filter (0.5–70 Hz). Continuous EEG files for each subject were
loaded into BRAIN ELECTRICAL SOURCE ANALYSIS software (BESA,
version 5.3, MEGIS, Gra¨felfing, Germany) and filtered digitally
with a high bandpassfilter of 0.16–30 Hz (6/12 dB octave). Before
averaging, the first responses of each of the five intensities were
excluded in order to reduce short-term habituation effects. For
artefact suppression, all trials were automatically excluded from
averaging when the voltage exceeded 650 mV in any of the 32
channels at any point during the averaging period. Data with a
100 ms pre stimulus and a 300 ms post stimulus baseline interval
were then inspected visually. On average 63% (65.228) artefact-
free sweeps per intensity were averaged separately for each
participant, which should lead to an appropriate signal-to-noise
ratio.
Serotonergic Dysfunction in Negative Symptoms
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e68650
Dipole Source Analysis (DSA) and Single Electrode
Estimation
Dipole source localization of the N1/P2-component of AEPs
was computed by means of the inverse solution as implemented in
BESA, using a spherical head model. DSA provides an important
methodological advance, because overlapping subcomponents of
the N1/P2-component in the primary as well as secondary
auditory cortex can be studied separately [50]. This is a pivotal
point, as primary auditory cortex is highly innervated by serotonin
compared to secondary auditory cortex [51]. Similar studies reveal
a high spatio-temporal accuracy with DSA [52,53]. Based on the
grand average over all subjects a dipole model was computed for
the 60 dB and 70 dB intensities with two regional sources (one for
each hemisphere). Several authors suppose a frontal protective
mechanism being activated during presentation of high tone
intensities [54,55]. Therefore a third regional source was added to
the frontal region for the high intensity dipole model computed for
the 90 and 100 dB intensities. These two models were applied to
the individual data sets (high intensity model to 60–70 dB, low
intensity model to 80–100 dB) in order to obtain the spatio-
temporal information of the brain activation. The methods have
been published in detail elsewhere [28,29,51].
Because the majority of studies on the LDAEP focused on the
N1/P2 component, which seems to be more internally consistent
and test-retest reliable than slopes based on other components
[56,57], the peak-to-peak N1/P2 amplitudes were used to quantify
differences in the responses to the different tone intensities.
Additionally to the DSA approach we analysed the data with a
scalp method, as recommended by our group [58], to facilitate
across-study comparisons. N1/P2 amplitudes were determined at
the Cz electrode and were re-referenced to linked mastoids. The
LDAEP was determined by the median of all slopes of each
possible connection between the five different N1/P2 amplitudes
corresponding to the five different intensities [29] for tangential
dipole activity of both hemispheres and Cz-electrode estimation
derived amplitudes. These values were used as the main variables
for statistical evaluation.
Statistical Analysis
Comparison of age and smoking status in patients and controls
was conducted with a t-test for independent samples and cross-
tabulation with x2 test, respectively. To test the association
between LDAEP values and the group factor (control group vs.
schizophrenic patients) we conducted a series of generalized linear
models (GLM) [59]. GLM was chosen because it allows for
variables that are not normally distributed in comparison to
familiar used methods as ANOVA or linear regression analysis.
LDAEP of the left and right hemisphere and from Cz-estimation
were entered as the dependent variables. The covariates age and
nicotine use were tested separately in bivariate analyses against
LDAEP using DSA. Distribution and link-function of the LDAEP
variables were chosen according to their graph and the goodness
of model fit indices. For this purpose we compared the Akaike’s
information criterion (AIC) and the Bayesian information criterion
(BIC) for the different distributions and link-functions. The best fit
to the data was finally obtained with a gamma distribution (right
skewed distribution) and log link-function. In all GLM a robust
estimator was used to reduce the effects of outliers and influential
observations. Group effects on LDAEP were displayed with mean
differences, whereas associations between continuous measures
and LDAEP were depicted with unstandardized regression
coefficients (B). In order to provide comparability among
predictors all continuous covariates were standardized using the
z-transformation. Wilcoxon-test was used to test if the medians
between left and right LDAEP differed significantly. Analyses were
carried out with SPSS version 20 for Windows.
Results
Demographics and psychopathology data for both groups are
summarised in Table 1. Although antipsychotic medication
estimated by CPZ-equivalent dose had a medium to strong effect
on psychopathological scales, the correlations did not reach the
level of statistical significance (PANSS general score; r =20.698,
p = 0.08; other scales r =20.31–0.44, p.0.1).
The LDAEP using DSA was significantly associated with the
group membership in both hemispheres (right: Wald = 10.094,
df = 1, p = 0.001; left: Wald= 7.791, df = 1, p = 0.005). Patients
with schizophrenia showed a significantly higher LDAEP than the
control group (Table 2, Figure S2). Results were adjusted for age
and nicotine use. The magnitude of the group effect on LDAEP on
both hemispheres was remarkably large, as indicated through the
standardized mean difference Cohen’s d = 1.04 (left) and d= 1.20
(right) (benchmarks are as follows: d = 0.3 depicts a small effect,
d = 0.5 a medium effect and d= 0.8 a large effect). No significant
differences in the LDAEP between the groups were found using
single electrode estimation at Cz (Wald = 0.057, df = 1, p = 0.811).
No significant differences between left and right LDAEP were
found, neither among the whole sample (Z=21.283, p = 0.200),
nor among schizophrenic patients (Z=21.153, p = 0.249) or the
control group (Z=20.524, p= 0.600).
Moreover, we observed a significant positive relationship
between the SANS subscales ‘‘affective flattening’’ (beta = 0.207,
p = 0.000), ‘‘anhedonia’’ (beta = 0.155, p = 0.016) and ‘‘attentional
impairment’’ (beta = 0.189, p= 0.015) and the LDAEP in the right
hemisphere in patients. SANS composite score (the sum of scores
for all items), which reflects severity of negative symptoms, was
also positively correlated with the right LDAEP (beta = 0.153,
p = 0.035) (Table 3). Depressive symptoms (BRMS and CDSS G
scale) (beta =20.372, p = 0.000; beta =20.305, p = 0.000) as well
as PANSS general score (beta =20.159, p = 0.026) were associ-
ated with the left LDAEP. Patients with higher scores on these
Table 1. Demographic and clinical data of the sample.
Patients Controls t/x2 p
N 13 13
Age (years) 35.0 (8.13) 35.4 (8.17) t = 0.120,
df = 24
0.905
Medication (CPZ) 707.0 (597.62) – – –
Smoking (yes/no) 69; 31 23; 77 x2= 5.571,
df = 1
0.018*
PANSS positive 15.46 (4.93) – – –
PANSS negative 18.39 (6.25) – – –
SANS composite score 31.31 (15.39) – – –
BRMS 6.31 (3.77) – – –
HAMD 17 8.69 (4.07) – – –
CDSS-G 3.15 (3.11) – – –
Data presented as % or mean 6 SD. Abbreviations: CPZ, Chlorpromazine Dose
Equivalence Ratios; PANSS, Positive and Negative Syndrome Scale; SANS, Scale
for Assessment of Negative Symptoms; BRMS, Bech-Rafaelsen Melancholia
Scale; HAMD, Hamilton Depression Rating Scale, CDSS-G, Calgary Depression
Rating Scale for Schizophrenia.
*p,0.05.
doi:10.1371/journal.pone.0068650.t001
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scales showed lower LDAEP (Table 4). As shown in Table 3 and 4
all other psychopathological scales were not significant. LDAEP
on both hemispheres were positively associated with medication by
means of CPZ-equivalent dose (beta = 0.162, p = 0.001 and
beta = 0.173, p = 0.030 for right and left hemisphere).
Discussion
The present study was designed to investigate the role of
serotonergic neurotransmission estimated by the LDAEP for the
psychopathology of negative symptoms in schizophrenia. Due to
the heterogeneity of the clinical concept of schizophrenia and its
limitations as a valid object for scientific investigation [60], the
level of psychopathological symptoms was chosen. We hypothe-
sized that the LDAEP in patients with predominant negative
symptoms would deviate from that of patients with predominant
positive symptoms and healthy controls, indicating a difference in
serotonergic neurotransmission. The results of this study provide
new evidence in schizophrenia research. We would like to
emphasize two remarkable findings. First, patients with schizo-
phrenia showed a significantly stronger LDAEP than the control
group. Based on the presumptions of the inverse relationship
between LDAEP and 5-HT, this may indicate a difference in
serotonergic neurotransmission. Moreover, the stronger LDAEP
in patients with schizophrenia is highly associated with negative
symptoms. Second, only the increased LDAEP in the right
hemisphere was associated with negative symptoms, underscoring
the effects of laterality in brain functions and brain activity in
schizophrenia. The single electrode estimation at Cz did not show
any significant differences between the groups, which may derive
from additional frontal source activation involved in high
intensities. This has also been reported by Hagenmuller et al. [58].
Our findings contrast with those of previous studies, which
showed that patients with schizophrenia had a weaker LDAEP
than healthy controls [37,38,39,40]. However, those studies were
not designed to control for LDAEP differences between positive
and negative symptoms. They focused on schizophrenic patients as
a self-contained group. Nevertheless, Juckel et al. [39] reported a
tendency toward a positive relationship between PANSS negative
score and LDAEP whereas Gudlowski et al. [37] found a negative
relationship between those scores. Our findings are contrary to the
results of Gudlowski et al. [37]. One explanation for inconsistent
findings could be due to a difference in methodology as sampling
biases, gender effects, intensity of stimuli and methods of
estimation (DSA vs. single-electrode) [32]. In particular, our data
were analysed with DSA method, whereas Gudlowski et al. [37]
used single-electrode estimation for LDAEP. According to
Hagenmuller et al. [58], studies using different methods are
difficult if not impossible to compare. Furthermore, the sample in
Gudlowski’s study included females and males. Even though some
studies reported no gender effects [29,40,61], others have
Table 2. LDAEP mean values in left and right hemisphere and
Cz electrode across groups.
Hemisphere Group Mean 95% CI Wald x2 (df) Sig
Left Controls 1.060 0.894–1.258 7.791 (1) 0.005*
Patients 1.450 1.230–1.710
Right Controls 0.905 0.781–1.050 10.094 (1) 0.001*
Patients 1.234 1.073–1.420
Cz Controls 0.150 0.116–0.194 0.057 (1) 0.811
Patients 0.142 0.105–0.192
Results are adjusted for age and nicotine use.
*p,0.01.
doi:10.1371/journal.pone.0068650.t002
Table 3. Associations between right-hemispheric LDAEP
values and clinical characteristics among patients.
Measures B 95%-CI Wald x2 (df) Sig
CPZ 0.162 0.069; 0.254 11.593 (1) 0.001*
PANSS positive 20.014 20.154; 0.125 0.041 (1) 0.840
PANSS negative 0.103 20.036; 0.243 2.114 (1) 0.146
PANSS composite score 20.086 20.241; 0.070 1.170 (1) 0.279
PANSS general 20.174 20.354; 0.006 3.574 (1) 0.059
SANS Affect 0.207 0.094; 0.321 12.908 (1) 0.000*
SANS Alogia 20.015 20.151; 0.121 0.047 (1) 0.829
SANS Avolition 20.101 20.228; 0.026 2.416 (1) 0.120
SANS Anhedonia 0.155 0.029; 0.282 5.779 (1) 0.016*
SANS Attention 0.189 0.036; 0.341 5.906 (1) 0.015*
SANS composite score 0.153 0.011; 0.296 4.451 (1) 0.035*
BRMS 0.054 20.129; 0.237 0.331 (1) 0.565
HAMD 17 20.049 20.204; 0.106 0.391 (1) 0.532
CDSS G 20.055 20.184; 0.074 0.695 (1) 0.404
Abbreviations: CPZ, Chlorpromazine Dose Equivalence Ratios; PANSS, Positive
and Negative Syndrome Scale; SANS, Scale for Assessment of Negative
Symptoms; BRMS, Bech-Rafaelsen Melancholia Scale; HAMD, Hamilton
Depression Rating Scale, CDSS-G, Calgary Depression Rating Scale for
Schizophrenia.
*p,0.05.
doi:10.1371/journal.pone.0068650.t003
Table 4. Associations between left-hemispheric LDAEP values
and clinical characteristics among patients.
Measures B 95%-CI Wald x2 (df) Sig
CPZ 0.173 0.160; 0.331 4.681 (1) 0.030*
PANSS positive 20.091 20.219; 0.037 1.935 (1) 0.164
PANSS negative 20.061 20.275; 0.152 0.320 (1) 0.572
PANSS composite score 20.007 20.237; 0.223 0.004 (1) 0.950
PANSS general 20.159 20.299; 20.019 4.962 (1) 0.026*
SANS Affect 20.073 20.256; 0.110 0.607 (1) 0.436
SANS Alogia 20.048 20.319; 0.224 0.118 (1) 0.731
SANS Avolition 20.120 20.329; 0.089 1.263 (1) 0.261
SANS Anhedonia 20.219 20.367; 20.071 8.406 (1) 0.004*
SANS Attention 20.028 20.276; 0.221 0.047 (1) 0.828
SANS composite score 20.137 20.294; 0.019 2.970 (1) 0.085
BRMS 20.372 20.493; 20.250 36.082 (1) 0.000*
HAMD 17 20.075 20.294; 0.143 0.457 (1) 0.499
CDSS G 20.305 20.409; 20.202 33.331 (1) 0.000*
Abbreviations: CPZ, Chlorpromazine Dose Equivalence Ratios; PANSS, Positive
and Negative Syndrome Scale; SANS, Scale for Assessment of Negative
Symptoms; BRMS, Bech-Rafaelsen Melancholia Scale; HAMD, Hamilton
Depression Rating Scale, CDSS-G, Calgary Depression Rating Scale for
Schizophrenia.
*p,0.05.
doi:10.1371/journal.pone.0068650.t004
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documented some effects on the LDAEP [62,63,64]. The study by
Juckel et al. (2008) [39] used comparable methodology to the
present study and some results are in line with our findings,
showing strong LDAEP in patients with negative symptoms
among schizophrenic patients. Compared to healthy controls, they
reported weaker LDAEP in the left hemisphere in patients, which
states a contrary result to our findings.
Nonetheless, our results are consistent with those of previous
research on neurotransmitter alterations in negative symptoms
and suggest the role of an impaired serotonergic system [12].
Although many studies on the direct involvement of the
serotonin system in schizophrenia exist, here we focus on
results concerning negative symptoms. Direct evidence is
provided from a post-mortem study, which reported a decreased
5-HT2 receptor density in frontal cortex in patients with
chronic schizophrenia [65]. Furthermore, a PET study showed
lower availability of 5-HT1A receptors in patients with
schizophrenia compared to healthy controls and receptor
binding was negatively associated with negative symptoms,
estimated by the PANSS scale [66]. Moreover, a genetic study
by Reynolds [67] gives support to an involvement of the
serotonergic system in the pathogenesis of negative symptoms,
since the 5-HT2C receptor promoter polymorphism is associ-
ated with negative symptoms. From studies on the mechanism
of action of atypical neuroleptics in negative symptoms an
indirect evidence for serotonergic involvement is provided. In
this context, it remains unclear why serotonin antagonists as
well as agonists have an impact on the serotonergic system and
improve the outcome of negative symptoms. Silver [20] suggests
that these pharmacologically distinct treatments may share
common final mechanism. This paradoxical finding needs
further investigation. Moreover, one has to consider that
different 5-HT receptors have opposite effects on the function
of neurons by means of inhibition and excitation [15]. Further
research is needed to clarify, if negative symptoms are caused
directly by a primary abnormality in serotonergic transmission
or in a secondary way via modulation of dopamine release
[11,68,69].
With regard to the laterality effect, the present results showed a
positive association between LDAEP and negative symptoms
(SANS subscale affective flattening, anhedonia and attentional
impairment, SANS composite score) in the right hemisphere, and
a negative association between LDAEP and depressive symptoms
(BRMS and CDSS G scale) in the left hemisphere in schizophrenic
patients. A possible explanation could be that the LDAEPs in
patients with high scores on depressive scales converge towards the
LDAEP values of healthy controls (weaker LDAEP). This
conclusion is in line with the literature about LDAEP in depressive
patients, where no significant effect on the LDAEP has been
shown [40,63,70]. Our results could also be due to serotonergic
interhemispheric asymmetry, respectively to a reduced leftward
asymmetry of brain structures of the auditory cortex in schizo-
phrenia as observed by Salisbury et al. [71] and Shenton et al.
[72]. At that juncture, that the role of the laterality effect in
schizophrenia and in particular in negative symptoms is not
known, interpretation is limited.
Nevertheless, our study is not without limitations: The sample
size was relatively small, which had an effect on the statistical
power. Furthermore, the effects of education were not considered.
With regard to the influence of attention to the LDAEP [48] and
given that patients with negative symptoms often show an
attention deficit during auditory performances [73], an objective
procedure controlling attention would have been necessary to add
further consistency to our findings. A biased effect of medication is
plausible since all patients were treated with atypical neuroleptics.
There was an association with CPZ-equivalent dose and LDAEP
found in both hemispheres in this study, indicating an elevated
LDAEP (and lower serotonergic activity) with higher medication
use. Furthermore, general symptoms rated on PANSS scale were
negatively related to medication in that they displayed a statistical
trend (p = 0.08). In a study by Juckel et al. [38] an increased
LDAEP after a treatment with atypical neuroleptics compared to
baseline was observed. Moreover, in a PET study, a trend toward
a decreased 5-HT2 receptor binding in prefrontal cortex was
found in neuroleptic treated patients, whereas neuroleptic naive
patients showed similar results as healthy controls [74]. As
negative symptoms also occur as pharmacological side effects
(secondary negative symptoms) it is debatable if the found
relationship between LDAEP and negative symptoms is an effect
of secondary negative symptoms. A distinction between primary
and secondary negative symptoms is not possible with contempo-
rary measurements of psychopathology [75,76]. On the other
hand, a study design including unmedicated chronic schizophrenic
patients is hardly realistic both for ethical reasons and practica-
bility. Further studies with more focus on the effect of medication
are therefore needed.
Another limitation is the possible influence of other neurotrans-
mitters on the LDAEP. There are genetic association studies and
challenge trials on possible influences of dopamine, glycine, and
nitric oxide [33,34,35,36]. As these studies point to a sensitivity of
the LDAEP also to neurotransmitter systems other than 5-HT, the
LDAEP’s specificity as a marker of serotonergic function is
challenged [32]. This has to be taken into account in the
interpretation of this study. Nevertheless, also these results are in
part heterogeneous, e.g. an association of the LDAEP with the
dopaminergic system by means of the COMT Val158Met-
polymorphism [34] could not be reflected in a dopaminergic
challenge trial [33].
In conclusion, the aim of the present study was to investigate the
LDAEP as an indicator of serotonin functioning within the
schizophrenic spectrum. In particular, we took account of the
heterogeneity of clinical diagnosis by examining the accurate
psychopathological symptoms. The results showed an association
between the serotonergic function estimated by the LDAEP and
the extent of negative symptoms directly. Our findings support the
idea of differential clinical features of schizophrenia and contribute
to the clarification of the aetiology of negative symptoms.
Supporting Information
Figure S1 Example of loudness dependence of auditory
evoked potentials (LDAEP). Auditory evoked activity of the
tangential dipole in the right hemisphere following auditory
stimulation of a 1000 Hz tone with different sound pressure levels
(60 to 100 dB SPL) over all subjects (n = 26).
(EPS)
Figure S2 Overall distribution of the loudness depen-
dence of auditory evoked potentials (LDAEP) values
between both groups. The boxplots represent medians,
quartiles and extreme values of the LDAEP variable in the left
(A) and right (B) hemisphere across healthy controls and patients
with schizophrenia.
(EPS)
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